NEW YORK — Klaus J. Busam, MD, director of the dermatopathology service at Memorial Sloan Kettering Cancer Center, highlighted the role of molecular profiling in melanoma diagnosis during his presentation at HemOnc Today Melanoma and Cutaneous Malignancies.
Busam focused on studies designed to evaluate gene mutation analysis for melanoma diagnosis. Topics included the use of gene mutation analysis in determining the distinction between melanoma and sarcoma, staging of primary melanoma vs. metastatic disease, and concerns in diagnosing melanoma vs. nevus.
“Mutation alone doesn’t give you the answer,” Busam said. “Mutations do not have a tight association with the phenotype. You need to put it in context with clinical and histopathologic data to make the right diagnosis. In essence, molecular studies can be an important piece of the diagnostic puzzle.”
Busam K. The role of molecular profiling in melanoma diagnosis. Presented at: HemOnc Today Melanoma and Cutaneous Malignancies; March 24-25, 2017; New York.
Disclosure: Busam reports no relevant financial disclosures.